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I.  INTRODUCTION 
 
[1]  Mary Doe is a human embryo preserved in liquid nitrogen, in an 
unnamed in vitro fertilization clinic.1  Mary Doe’s name was given by an 
organization dedicated to advocating for equal humanity and personhood 
of pre-born children, including “children in vitro.”2  In response to 
President Clinton’s policy favoring embryonic stem cell [hereinafter ES-
cell] research, the organization filed suit on behalf of Mary Doe, and all 
other frozen human embryos similarly situated, seeking a permanent 
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1
 Doe v. Shalala, 122 Fed. App’x 600, 601 (4th Cir. 2004). 
2
 Petition for a Writ of Certiorari, Doe v. Thompson, No. 04-1642, 2005 WL 1361857 
(2005). 
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injunction against any and all plans to undertake human ES-cell 
experimentation.3 
 
[2]  In August 2001, while the lawsuit was pending, President Bush 
announced a new policy concerning human ES-cell research.4  The new 
policy limited federal funding for human ES-cell research only to projects 
involving already-existing stem cell lines.5  No federal funds would be 
used to further research involving the derivation of new stem cell lines 
from intact embryos like Mary Doe.6  As a result, the district court granted 
the government’s motion to dismiss the case as moot, because Mary Doe 
would no longer be threatened.7  The Fourth Circuit Court of Appeals 
affirmed the decision.8 
 
[3]  Even in the absence of a direct ban, the government has numerous 
means that it can use to suffocate a disfavored subject matter.  The U.S. 
policy on human ES-cell research is an example.  Human ES-cell research 
has been primarily reliant upon private funding since its inception in the 
late 1990s.9  Though federal money is prohibited from funding research 
that uses newly developed human ES-cell lines,10 and few states have 
supported such research,11 the lack of public funding does not fatally 
impact human ES-cell research in this country. 
 
[4]  However, the straw that will break the camel’s back may have been 
placed by the U.S. Supreme Court’s decision in KSR International Co. v. 
                                                 
3
 Doe, 122 Fed. App’x at 601.  In addition, the organization also sought a declaration that 
Mary Doe is entitled to due process of law and the equal protection of the laws under the 
Fourteenth Amendment.  Id. 
4
 Id. 
5
 Id. 
6
 Id. at 603. 
7
 Id. at 601. 
8
 Id. 
9
 Leroy Walters, Human Embryo Research: Lessons from History, 293 SCI. 1401, 1401 
(2001), available at http://www.sciencemag.org/cgi/content/summary/293/5534/1401. 
10
 R. John Davenport, Drumming Up Dollars for Stem Cell Research, 123 CELL 1169, 
1169 (2005), available at http://www.sciencedirect.com/science/journal/00928674 
(follow “Volume 123” hyperlink; then follow hyperlink under “Drumming Up Dollars 
for Stem Cell Research.”). 
11
 Id. at 1171. 
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Teleflex, Inc.12  The Court’s decision—which is expected to have grave 
adverse effects on the issuance of biotechnology patents—along with the 
Patent and Trademark Office’s decision to revoke landmark human ES-
cell patents,13 has sent a strong message to private investors that their 
investment in human ES-cell research is unlikely to receive patent 
protection, and therefore, they are not likely to gain monetary reward from 
such investment.14  The withdrawal of private funding from human ES-
cell research is foreseeable. 
 
[5]  Although human ES-cell research is not expressly banned, due to the 
lack of public funding and the lack of incentives for private investment, 
the joint efforts of the Executive Branch and the Supreme Court have 
inadvertently stifled such research.  Without prompt action taken by 
Congress, human ES-cell research in this country may cease. 
 
[6]  As suggested by John A. Robertson, if direct bans are imposed on 
privately- funded human ES-cell therapies or the research necessary to 
produce them, a greater role for the judiciary is favored.15  Though in the 
absence of a direct ban, the stacking adverse effects of U.S. policy on 
human ES-cell research have amounted to an effect equivalent to a direct 
ban and has reached the point that a greater role for the judiciary is 
favored.  Unfortunately, a legislative effort attempting to support human 
ES-cell research may have a hard time surviving the Supreme Court’s 
muster in light of Gonzales v. Carhart,16 a decision which has extensively 
expanded the state’s interest in promoting and preserving unborn life.17 
 
[7]  In this article, Part II seeks to clarify the basic information regarding 
human ES-cell research, the international scientific community’s efforts in 
self-regulating such research, and alternative technologies which, although 
premature, have inspired politicians and vice versa.  Part III examines the 
congressional and state efforts and obstacles in seeking to fund human ES-
                                                 
12
 KSR Int’l Co. v. Teleflex, Inc., 127 S. Ct. 1727, 1734-35 (2007). 
13
 Dillon Beardsley, A Two-Front Assault on the Stem Cell Patents, 6 J. MARSHALL REV. 
INTELL. PROP. L. 501, 513 (2007). 
14
 Id. at 519. 
15
 See John A. Robertson, Embryo Culture and the “Culture of Life”: Constitutional 
Issues in the Embryonic Stem Cell Debate, 2006 U. CHI. LEGAL F. 1, 7 (2006). 
16
 Gonzales v. Carhart, 127 S. Ct. 1610 (2007). 
17
 See generally id. 
Richmond Journal of Law & Technology Volume XIV, Issue 4 
 
4  
cell research with public money.  Part IV examines the revocation and 
restriction of human ES-cell patents, and the impact on the supply of 
private funding.  Finally, Part V explores the Supreme Court’s latest 
teachings of abortion jurisprudence, which may shed some light on the 
Court’s views regarding human ES-cell research. 
 
II.  SCIENTIFIC BACKGROUND AND PROSPECT 
 
[8]  Human ES-cell research has been dubbed a promising technology that 
will eventually lead to the treatment of currently untreatable diseases.18  Its 
promising future however, has been accompanied by moral and ethical 
concerns arising out of the destruction of human embryos.19  Members of 
the international scientific community, such as the International Society 
for Stem Cell Research (“ISSCR”), have sought to self-regulate such 
research among researchers worldwide by formulating general 
guidelines.20  Other scientists also seek to explore alternative technologies, 
such as the reprogramming phenomenon or the use of “dead” embryos, to 
alleviate the ethical concerns.21  Though these alternative technologies are 
not mature at this stage, they have inspired politicians in formulating stem 
cell policy and relevant legislation.22   
 
A.  WHAT IS AN EMBRYONIC STEM CELL? 
 
[9]  Embryonic stem cells are cells which can become all cell types of the 
body.23  The proliferative nature and the developmental potential of 
human ES-cells have indicated a promising future of an essentially 
                                                 
18
 See National Institutes of Health, Stem Cells and Diseases, 
http://stemcells.nih.gov/info/health.asp (last visited Mar. 23, 2008).    
19
 See Louis Guenin, International Society for Stem Cell Research, The Ethics of Human 
Embryonic Stem Cell Research, http://www.isscr.org/public/ethics.htm (last visited Mar. 
23, 2008).   
20
 See infra note 35 and accompanying text.   
21
 Alan Boyle, Reprogramming Complicates Stem Cell Debate, (Aug. 10, 2005), 
http://www.msnbc.msn. 
com/id/ (“cell reprogramming avoids the political debate . . . .”).   
22
 See id. 
23
 National Institutes of Health, Stem Cell Basics, 
http://stemcells.nih.gov/info/basics/basics5.asp (last visited June 13, 2007). 
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unlimited supply of specific cell types for both basic research and 
transplantation therapies.24 
 
[10]  It is worth noting that the embryos from which human ES-cells are 
derived are not obtained from eggs fertilized in a woman’s body.25  
Instead, embryonic stem cells for research purposes are obtained from 
embryos that develop from eggs which have been fertilized in vitro in a 
fertilization clinic.26  The embryos remain at a stage before the time that 
implantation would normally occur in the uterus.27  The embryos from 
which human ES-cells are derived are donated for research purposes with 
the informed consent of the donors,28 and do not in any way look like a 
fetus or a newborn infant.29  Typically, these embryos are four or five days 
old after fertilization and are a hollow microscopic ball of cells called the 
blastocyst.30  The first differentiation event in human embryos usually 
occurs at approximately five days of development.31  However, embryonic 
stem cells can remain undifferentiated if they are grown under certain 
conditions.32 
 
[11]  Scientists are trying to control the differentiation of embryonic stem 
cells in order to generate cultures of specific types of differentiated cells 
such as heart muscle cells, blood cells, or nerve cells.33  If scientists can 
develop a reliable “directed differentiation” technique, they may be able to 
use the resulting differentiated cells to treat currently untreatable diseases 
                                                 
24Junying Yu & James A. Thomson, Embryonic Stem Cells, Regenerative Medicine 1 
(2006), 
http://stemcells.nih.gov/staticresources/info/scireport/PDFs/Regenerative_Medicine_200
6.pdf.  
25
 National Institutes of Health, Stem Cell Basics, 
http://stemcells.nih.gov/info/basics/basics3.asp (last visited June 13, 2007). 
26
 Id. 
27
 Yu & Thomson, supra note 24. 
28
 Stem Cell Basics, supra note 25. 
29
 Gina Kolata, Embryonic Cells, No Embryo Needed: Hunting for Ways Out of an 
Impasse, N.Y. TIMES, Oct. 11, 2005 at F1, available at 
http://www.nytimes.com/2005/10/11/health/11stem.html. 
30
 Id. 
31
 Yu & Thomson, supra note 24. 
32
 Stem Cell Basics, supra note 25. 
33
 Id. 
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such as Parkinson’s disease, diabetes, traumatic spinal cord injury, and 
heart disease.34 
 
[12]  Regardless of the seemingly promising future of human ES-cell 
research, the ethical concerns arising from the destruction of human 
embryos have never eased.  Responding to the concerns, the scientific 
community has basically adopted two approaches, namely formulating 
guidelines for self-regulation, and exploring alternative technologies 
seeking to replace the use and destruction of viable human embryos. 
 
B.  THE ISSCR GUIDELINES 
 
[13]  The scientific communities did not ignore the ethical concerns 
surrounding human ES-cell research.  The ISSCR has formulated a set of 
guidelines for researchers worldwide to follow.35  Nevertheless, the 
ISSCR acknowledged that the guidelines should be “subservient to all 
applicable laws and regulations of the country or region where the actual 
research takes place.”36 
 
[14]  Among other things, the ISSCR guidelines have expressly prohibited 
scientists from using human embryos to conduct certain experiments.  For 
example, human reproductive cloning, and the interbreeding of animals 
likely to harbor human gametes are expressly prohibited.37  The guidelines 
also ban the in vitro culture of human embryos which are beyond fourteen 
days or the formation of the primitive embryonic streak.38        
 
[15]  In addition, the ISSCR cautioned that financial considerations of any 
kind should not amount to an undue inducement involving egg 
                                                 
34
 Id. 
35
 George Q. Daley et al., The ISSCR Guidelines for Human Embryonic Stem Cell 
Research, 315 SCI. 603, 603 (2007), available at 
http://www.sciencemag.org/cgi/content/full/315/5812/603?rss=1.  The guidelines were 
written by scientists, ethicists, and legal experts from fourteen countries.  Id.  The ISSCR 
guidelines are available at 
http://www.isscr.org/guidelines/ISSCRhESCguidelines2006.pdf.  
36
 Id. 
37
 Id. 
38
 Id.  The rationale for the “14-day limit” is that embryos before fourteen days since 
fertilization have not begun to initiate organogenesis because they have not established 
even the most rudimentary rostral and caudal orientation.  Id. at 604. 
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procurement.39  For the research use of embryos generated with donated 
gametes,40 explicit consent from both gamete donors is required.41  The 
U.S. National Academy of Sciences (“NAS”) has formulated similar 
guidelines, but called for a precise form of stem cell research oversight.42 
 
[16]  Both the ISSCR and NAS guidelines have evidenced that the 
scientific communities have reached a general consensus with regard to 
the regulation of human ES-cell research.  The guidelines have provided a 
sound foundation that a government may efficiently adopt a regulatory 
system overseeing such research if the government believes that regulation 
is better than prohibition in the context of human ES-cell research. 
 
[17]  Nevertheless, ethical concerns over human ES-cell research not only 
urged scientific communities to formulate guidelines for self-regulation, 
they also motivated scientists to seek alternative technologies to replace 
the use of viable human embryos.  The most notable examples are the 
reprogramming phenomenon, and the proposal of deriving stem cells from 
embryos which are considered “dead.” 
 
C.  ALTERNATIVE APPROACHES: REPROGRAMMING PHENOMENON 
 
[18]  Reprogramming is a technique by which scientists seek to revert 
adult stem cells so that the adult stem cells are indistinguishable from 
                                                 
39
 Id. 
40
 Mary Lyndon Shaley, Collaboration and Commodification in Assisted Procreation: 
Reflection on an Open Market and Anonymous Donation in Human Sperm and Eggs, 36 
LAW & SOC’Y REV. 257, 258 (2002) (“A gamete can be either an egg or a sperm; a 
gamete is a cell that contains half the genetic material needed for human procreation.”).   
41
 Daley et al., supra note 35.  The ISSCR also proposed that, in the future, “informed 
consent for all gamete donors should include the possible use of donated materials and 
their derivatives in human stem cell research.”  Id. 
42
 Id. at 603; see also National Research Council & Institute of Medicine, Guidelines for 
Human Embryonic Stem Cell Research, available at  
http://books.nap.edu/openbook.php?record_id=11278&page=R2; Frederick Grinnell, 
Defining Embryo Death Would Permit Important Research, 49 THE CHRON. REV. B13 
(2003), available at 
http://www4.utsouthwestern.edu/FrederickGrinnell/GrinnellWebMisc/embryodeath.pdf.  
Alternatively, Frederick Grinnell suggested that the United States may establish a process 
analogous to that used in England, which requires the licensing of all in vitro production 
and use of human embryos in the public and private sectors.  Id. 
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embryonic stem cells.43  The ISSCR Guidelines do not include adult stem 
cell research.44  Several groups of scientists have claimed success in 
reprogramming fetal mouse cells45 and have expressed a belief that the 
same technique can also work on adult cells.46 
 
[19]  Adult stem cells and embryonic stem cells differ not only in the 
number of cells present, but also in the type of differentiated cells they can 
become.47  Differentiation of adult stem cells is generally limited only to 
the cell types of their tissue of origin,48 while embryonic stem cells can 
become all cell types of the body.49  In addition, adult stem cells are rare 
in mature tissues and the method to proliferate them in large numbers is 
currently unavailable, while embryonic stem cells can be relatively easily 
grown in large numbers.50 
 
[20]  Optimists may assert that the success of reprogramming in fetal 
mouse cells essentially means that the limitation of adult stem cells, both 
in the number of cells and in the type of differentiated cells they can 
become, will soon be lifted.  However, that is not so.  In reality, “[i]t’s still 
a long road to potential therapies with reprogrammed adult cells.”51  
Though scientists can now reprogram fetal mouse cells, it does not 
necessarily guarantee that they can reprogram human adult cells in the 
foreseeable future.  Furthermore, one group of scientists has observed that 
the offspring of the chimeras developed from reprogrammed fetal mouse 
cells have a high incidence rate of tumor, because the technology requires 
the use of viruses as vectors.52  It is one of the major problems that needs 
to be solved before such a technique can be applied to humans.  Therefore, 
                                                 
43
 Constance Holden, Stem Cells: Teams Reprogram Differentiated Cells—Without Eggs, 
316 SCI. 1404, 1404 (2007), available at 
http://www.sciencemag.org/cgi/content/full/316/5830/1404a.  
44
 Daley, supra note 35, at 603. 
45
 Holden, supra note 43. 
46
 Id. 
47
 Stem Cell Basics, supra note 25. 
48
 Id. 
49
 Id. 
50
 Id. 
51
 Holden, supra note 43, at 1405. 
52
 Id. at 1404.  The scientists used retroviral vectors to induce the reprogramming 
phenomenon in fetal mouse cells, and found that the retroviral vectors can also turn on 
cancer-causing genes.  Id. 
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based on the unsolved problems of the reprogramming phenomenon, using 
adult stem cells is not yet available and is not currently foreseeable as an 
effective alternative to embryonic stem cells. 
 
D.  ALTERNATIVE APPROACHES: DERIVING STEM CELLS FROM “DEAD” 
EMBRYOS 
 
[21]  In addition to the reprogramming phenomenon, scientists have also 
proposed that stem cells may be derived from embryos which are literally 
“dead.”  It is suggested that “dead” embryos may contain some healthy 
stem cells.53  A group of scientists proposed a new concept of “death,” 
which is only applicable to embryos.54  Unlike traditional concepts such as 
heart and lung failure, or brain death, scientists proposed that “an embryo 
is dead when most of its cells have naturally and irreversibly stopped 
dividing.”55 
 
[22]  Many of the frozen embryos stored by in vitro fertilization clinics are 
not viable for implantation.56  Scientists hypothesized that stem cell lines 
can be derived from “embryos that were created during in-vitro 
fertilization procedures but whose cells had stopped dividing naturally.”57  
Scientists reasoned that such embryos were “dead,” because they could 
not continue growing even if they were implanted in a womb.58  These 
                                                 
53
 Gautam Naik, The Devout Doctor’s Prescription for Stem-Cell Research, WALL ST. J., 
June 16, 2007, at A10. 
54
 Id. 
55
 Id.  Alternatively, Frederick Grinnell suggested that embryonic death may be defined 
as “the failure of an embryo to implant itself successfully in a uterus” or “the loss of 
integration or the inability to develop.”  Grinnell, supra note 42. 
56
 Naik, supra note 53. 
57
 Id.  As Frederick Grinnell has argued, if the ethical considerations and regulatory 
strategies now have made it possible to use cells and tissues derived from aborted fetuses 
to study human development and seek new medical therapies, the same should be 
applicable to dead embryos and their cells.  Grinnell, supra note 42. 
58
 Naik, supra note 53; see also Helen Pearson & Alison Abbott, Stem Cells Derived from 
“Dead” Human Embryos, 443 NATURE 376 (2006).  Scientists in Spain derived a stem 
cell line from “arrested” embryos.  “Arrested” embryos were those that had stopped 
dividing for twenty-four or forty-eight hours after reaching various stages of 
development.  Id. 
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embryos stop growing because of genetic abnormalities.59  Many of them 
have a mixture of normal and abnormal cells.60 
 
[23]  Other scientists questioned the viability of this proposal.  If the 
embryos stopped dividing because of their genetic errors, the genetic 
defects may be transmitted to patients who receive tissue transplants 
derived from these embryos.61  Another concern is whether the embryos 
are really “dead.”  It is cautioned that “[i]n our haste to obtain what we 
want, we may be killing an embryo . . . .”62 
 
[24]  A proposal cannot be an effective alternative if it raises new 
concerns while it does not solve the problems that it seeks to resolve.  As 
previously mentioned, one major concern of ES-cell research is that it 
“kills” embryos.63  Modifying the definition of “death,” as some scientists 
have suggested, does not change the underlying fact of whether an embryo 
is dead or not.  Proposing a new definition of “death” different from that 
which has traditionally applied to humans is arguably acknowledging that 
embryos are not human beings. 
 
[25]  The alternative technologies, such as the reprogramming 
phenomenon and deriving stem cells from “dead” embryos, are not 
reliable at this stage.  Nonetheless, they have served as the basis for the 
governmental policy and the congressional legislation on the issue of 
human ES-cell research. 
 
 
 
 
 
 
 
                                                 
59
 Naik, supra note 53. 
60
 Id. 
61
 Id. 
62
 Id.  Other scientists also questioned that there is no way to prove that an arrested 
embryo would have stopped growing if it had been put into a woman’s womb rather than 
a lab dish.  It leaves open the possibility that it was the lab conditions that halted the 
embryos’ growth.  See Naik, supra note 53. 
63
 See supra §II. 
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III.  GOVERNMENTAL POLICY AND CONGRESSIONAL LEGISLATION 
 
[26]  The battle between President Bush and Congress on the stem cell 
issue began with an announcement made by the president on August 9, 
2001.64  The president announced a policy that would allow federal funds 
to be used for research only on stem cell lines already in existence at the 
time of the announcement, “where the life and death decision has already 
been made.”65  According to the National Institute of Health (“NIH”), at 
the time of the announcement there were sixty-four stem cell lines 
available worldwide.66  However, only twenty of these were derived in the 
United States.67  The majority of cell lines were derived in Sweden, 
Australia, India, and Israel.68  Later, the Secretary of Health and Human 
Services, Tommy Thomson, acknowledged before a Senate Committee 
that only twenty-four to twenty-five of the sixty-four cell lines were in fact 
established.69 
 
[27]  Regardless of the small number of stem cell lines available, the 
president also sought to justify his policy by partly relying on the 
preliminary research that stem cells may be derived from adult cells.70  
Therefore, in his view, destruction of more embryos was not necessary.  
The president’s belief led to his two vetoes on congressional efforts in 
funding research utilizing stem cell lines which were derived after the 
presidential announcement.71  
                                                 
64
 President Discusses Stem Cell Research, 
http://www.whitehouse.gov/news/releases/2001/08/20010809-2.html (last visited Mar. 
24, 2008); see also Robertson, supra note 15, at 2. 
65
 President Discusses Stem Cell Research, supra note 64. 
66
 AAAS Ctr. for Sci., Tech., and Cong., AAAS Policy Brief: Stem Cell Research, 
http://www.aaas. 
org/spp/cstc/briefs/stemcells/index.shtml (last visited Mar. 6, 2008). 
67
 Id. 
68
 Id. 
69
 Id.  Scientists were also concerned about the safety of the cell lines which were derived 
before a new technique was available, because most of the cell lines were developed in a 
culture with the help of mouse stem cells which could potentially introduce animal 
viruses dangerous to humans. 
70
 President Discusses Stem Cell Research, supra note 64. 
71
 Deb Riechmann, Bush to Veto Stem Cell Bill, S.F. CHRON., June 20, 2007, available at 
http://www.sfgate.com/cgi-
bin/article.cgi?f=/n/a/2007/06/19/national/wl173912D22.DTL&type= 
politics. 
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A.  CONGRESSIONAL EFFORTS IN FUNDING HUMAN ES-CELL RESEARCH 
 
[28]  Congressional debate concerning human ES-cell research has 
centered on whether federal funding should cover such research.  In 2006 
and 2007, President Bush chose to use his veto pen twice on the stem cell 
issue.72  The Congressional efforts to expand federal funding to newly 
derived stem cell lines has been impeded by the vetoes, regardless of a 
Gallup poll showing that fifty-six percent of Americans said they favor 
using taxpayer money for the research.73 
 
[29]  Federal grants have played a critical role in the biotechnology 
industry by providing early-stage or seed funding to companies engaged in 
pioneer research.74  It is true for the industry as a whole, and it is true for 
human ES-cell research, which is a subset of the biotechnology industry.  
Particularly, the NIH is one of the major contributors to the federal grants 
used to fund biotechnology research.75  However, because congressional 
efforts in funding human ES-cell research were aborted following 
President Bush’s vetoes, the NIH has withheld federal grants to fund such 
research.76     
 
[30]  The impact of the policy on human ES-cell research is not limited 
only to the lack of funding.  It has far-reaching effects, which could 
impede and burden scientists conducting the research.  For instance, 
scientists working at a university have to raise private money to build new 
laboratories that duplicate facilities the university already has.77  This is 
                                                 
72
 Id. 
73
 Margaret Talev, Republicans Walk a Fine Line for Bipartisan Stem Cell Push, 
SACRAMENTO BEE, Apr. 3, 2006, available at 
http://dwb.sacbee.com/content/politics/story/14238209p-15058709c.html.  According to 
the Gallop poll, between 2002 and 2005, the percentage of adults who found embryonic 
stem cell research to be morally acceptable rose from fifty-two to sixty.  Id. 
74
 Lauren E. Komsa, Save America’s Biotechnology Industry Research Act: Support for 
Biotechnology or Corporate Welfare?, 25 BIOTECH. L. REP. 534, 537 (2006). 
75
 Id.  For instance, in 2003, the NIH was the second largest contributor to the federal 
funding program under the Small Business Innovation Research Act.  The Department of 
Defense was the largest contributor in the same year.  Id. 
76
 See Lee Silver, George Orwell Bush: The Latest Stem Cell Veto, AM. COUNCIL ON SCI. 
AND HEALTH, (June 21, 2007), http://acsh.org/factsfears/newsid.979/news_detail.asp. 
77
 Scientist Hopes for Stem Cell Success, CBS NEWS, Feb. 26, 2006, available at 
http://www.cbsnews. 
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because scientists are not permitted to work with new stem cell lines in a 
university’s laboratory (which often operates on federal funds), even 
though the scientists’ other research projects receive federal funds.78  The 
restriction on federal funding makes stem cell research very costly and 
time-consuming.79 
 
[31]  Nevertheless, the White House has signaled its “support for 
legislation that provides federal funding for stem-cell research using 
embryonic cells that have no chance of surviving.”80  The Hope Offered 
through Principled and Ethical Stem Cell Research Act (“HOPE Act”)81 
sought to allow scientists to conduct research on embryos that “they 
determine are incapable of surviving in the womb but whose stem cells are 
still viable for research.”82  The bill would allow federal funding for 
“research on stem cells from embryos that have died during fertility 
treatment.”83  The White House acclaimed the bill, stating that, “[b]y 
intensifying support for nondestructive alternatives, we can advance 
medical research in valuable ways while respecting ethical boundaries.”84 
 
[32]  As explained in Part II, modifying the definition of death for 
embryos may not be convincing even for opponents of human ES-cell 
research.  The question remains whether the embryos can, in fact, be 
deemed dead.  More importantly, according to some scientists, the genetic 
                                                                                                                         
com/stories/2006/02/23/60minutes/printable1341635.shtml. 
78
 Id. 
79
 Id. 
80
 Gregory Lopes, White House Backs Stem-Cell Bill, WASH. TIMES, Apr. 6, 2007, 
available at 2007 WLNR 6756279.  The bill was authored by Sen. Johnny Isakson, 
Georgia Republican.  Id. 
81
 See Library of Congress, http://thomas.loc.gov/cgi-
bin/query/D?c110:1:./temp/~c1108n9QRg:: (last visited Mar. 23, 2008). 
82
 Lopes, supra note 80. 
83
 Id.  The bill defined “naturally dead” as “having naturally and irreversibly lost the 
capacity for integrated cellular division, growth, and differentiation that is characteristic 
of an organism, even if some cells of the former organism may be alive in a disorganized 
state.”  Hope Offered through Principled and Ethical Stem Cell Research Act, S. 30, 
110th Cong. § 498D (f) (1) (as passed by Senate, Apr. 11, 2007). 
84
 White House Supports Stem Cell Bill that Would Allow Research On Embryonic Stem 
Cells With No Chance of Survival, MED. NEWS TODAY, Apr. 11, 2007, available at 
http://www.medicalnewstoday.com/ 
printerfriendlynews.php?newsid=67364. 
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defects of the “dead” embryos may be transmitted to patients receiving 
stem cells derived from the embryos.85 
 
[33]  Although the federal government has restricted its funding only to 
research utilizing a couple dozen existing stem cell lines, California has 
enacted laws authorizing the funding of stem cell research with state 
money.  However, the State was prevented from releasing the money 
because of lawsuits. 
 
B.  STATE EFFORTS IN FUNDING HUMAN ES-CELL RESEARCH 
 
[34]  Few states have passed laws providing state funding for stem cell 
research, with California being one of the few.86  In 2004, over 59.1% of 
voters in California approved Proposition 71: The California Stem Cell 
Research and Cures Act.87  The new law would provide funding of nearly 
$3 billion for human ES-cell research over a ten-year period.88  However, 
California’s support of human ES-cell research is conditional.  Proposition 
71 forbids funding for human reproductive cloning.89  In fact, the ban on 
human reproductive cloning was added to the California Constitution.90 
 
[35]  Though the new law attracted some of the best researchers in the 
field to California, lawsuits challenging Proposition 71 under the state 
constitution have prevented the state from releasing the money.91  In 2007, 
                                                 
85
 See Human Embryonic Stem Cells Extracted from Dead Embryos, Sept. 24, 2006, 
http://www. 
futurepundit.com/archives/003747.html (last visited Apr. 2, 2008). 
86
 Jodi Rudoren, Stem Cell Work Gets States’ Aid after Bush Veto, N. Y. TIMES, July 25, 
2006, at A1, A16.  In addition to California, Illinois offered $5 million in grants for stem 
cell research.  Connecticut, Maryland, and New Jersey also allocated state resources for  
research.  Id.  However, in November 2007, New Jersey voters rejected a ballot measure 
by a 53-47% margin that would have permitted the state to borrow $450 million for stem 
cell research.  David W. Chen, New Jersey Voters Defeat Stem Cell Measure, N.Y. 
TIMES, Nov. 7, 2007, at B1. 
87
 Stem Cell Research: Summary from the 2004 Ballot Pamphlet, CA. HEALTH FOUND., 
available at http://www.healthvote.org/index.php/site/prop_home/C28/.  
88
 Id. 
89
 Proposition 71 § 4, available at 
http://www.sos.ca.gov/elections/bp_nov04/prop_71_text_of_ 
proposed_law.pdf. 
90
 Id.  
91
 Scientist Hopes for Stem Cell Success, supra note 77. 
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the court in California Family Bioethics Council v. California Institute for 
Regenerative Medicine92 held that “Proposition 71 suffers from no [state] 
constitutional or other legal infirmity.”93  The court further expressed its 
regret concerning the delay, stating: 
 
[T]he objective of the proposition is to find, “as speedily as 
possible,” therapies for the treatment and cure of major 
diseases and injuries, an aim the legitimacy of which no 
one disputes.  The very pendency of this litigation, 
however, has interfered with implementation [of 
Proposition 71] for more than two years.94 
 
[36]  The California state court’s holding did not clear all of the clouds.  
Stem cell research has been primarily relying on private money since its 
inception.95  Even in the absence of a direct ban, the government has 
numerous means to discourage private investment, which in turn have the 
same effect as a direct prohibition.  One of the most effective ways to 
achieve that goal is by restricting issuance of patents to inventions flowing 
from human ES-cell research. 
 
IV.  PATENTABILITY AS A MEANS TO AFFECT PRIVATE FUNDING 
 
[37]  The first human ES-cell isolation reported in 1998 was not eligible 
for funding from the NIH, because the congressional ban on appropriating 
public funds for such research had been in effect since 1995.96  Before 
2001, no public funding was ever provided for human ES-cell research in 
this country.97  Rather, human ES-cell research in the United States had 
been primarily relying on the support of private investment.98 
 
[38]  Even though stem cell research may lack public funding, if the patent 
system can provide incentives and predictable business opportunities to 
                                                 
92
 Cal. Family Bioethics Council v. Cal. Inst. for Regenerative Med., 147 Cal. App. 4th 
1319 (Cal. Ct. App. 2007). 
93
 Id. at 1373. 
94
 Id. 
95
 AAAS Ctr. for Sci., Tech., and Cong., supra note 66. 
96
 See id. 
97
 Id. 
98
 Id. 
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attract private investment, private money will continue to support such 
research (even in the absence of the endorsement by governmental 
funding).  Unfortunately, the Supreme Court’s recent decision in KSR 
International Co. v. Teleflex, Inc.,99 has sent a strong message to the 
biotechnology industry, which includes human ES-cell research.100  KSR 
International stands for the idea that it may be unrealistic to expect the 
patent system to continue to play a role in attracting private investment. 
 
[39]  Private investment, specifically venture capital funding, is essential 
to the biotechnology industry.101  It provides financing to most of the 
industry’s pioneers.102  However, venture capitalists usually rely on certain 
kinds of “government endorsement” to determine whether to finance a 
particular technology.103  For instance, receipt of a federal grant will make 
the recipient company which owns the new technology more attractive to 
a venture capitalist.104  In turn, the venture capitalist will provide the 
majority of the funding.105 
 
[40]  Because human ES-cell research has generally been excluded from 
receiving federal funding, the remaining alternative that a venture 
capitalist may deem as a governmental endorsement concerning human 
ES-cell research is a predictable system that would grant patents to 
inventions flowing from such research.  On the other hand, the lack of 
federal funding, in addition to an unpredictable patent system, would have 
a stacking effect on suffocating human ES-cell research, even if the 
government does not expressly prohibit the research. 
 
A.  PATENTABILITY 
 
[41]  The isolation of a human ES-cell in the United States was first 
reported in November 1998 by Dr. James A. Thomson, biologist at the 
                                                 
99
 KSR Int’l Co. v. Teleflex Inc., 127 S. Ct.1727 (2007). 
100
 See generally id. 
101
 Komsa, supra note 74, at 535. 
102
 Id.  Approximately ninety-eight percent of research and development investment in 
the biotechnology industry comes from the private sector.  See infra note 144, at 9.  
103
 Id. 
104
 Komsa, supra note 74, at 537. 
105
 Id. 
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University of Wisconsin, Madison.106  Dr. Thomson’s research was not 
eligible for federal funding.107  Instead, the research was supported by 
Geron Corporation of Menlo Park, California, and the Wisconsin Alumni 
Research Foundation (“WARF”).108 
 
[42]  Dr. Thomson and his colleagues were issued a patent in March 
2001.109  Prior to October 2004, approximately thirty-eight patents 
claiming human ES-cell or process had been issued by the U.S. Patent and 
Trademark Office (“PTO”).110  Nevertheless, the “Thomson patents” on 
human ES-cells were overturned by the PTO in March 2007111 after both 
the Foundation for Taxpayer and Consumer Rights (“FTCR”) and the 
Public Patent Foundation (“PUBPAT”) requested reexamination of 
them.112  Though the patents were revoked by the PTO, WARF has the 
option to take the case to federal court if the PTO affirms the 
revocation.113  However, it is unlikely that a federal court will rule in favor 
of the patent holders following the Supreme Court’s recent decision in 
KSR International.114 
 
B.  INVALIDATION OF THE THOMSON PATENTS 
 
[43]  The Thomson patents include three patents covering the human ES-
cell line and methods of obtaining and culturing the cells, which were 
derived by Dr. James A. Thomson.115  They were the first human ES-cell 
                                                 
106AAAS Ctr. for Sci., Tech., and Cong., supra note 66. 
107
 Id. 
108
 Id. 
109
 Mark L. Rohrbaugh, Intellectual Property Issues Surrounding Embryonic Stem Cell 
Research, REGENERATIVE MED. 53 (2006), available at 
http://stemcells.nih.gov/staticresources/info/scireport/PDFs/ 
Regenerative_Medicine_2006.pdf. 
110
 Id. 
111
 Alex Lash,  A Victory for “Obviousness” in Biotechnology, 5 IP L. & BUS. 18 (June 
2007). 
112
 Two Groups Try for Revocation of Human Embryonic Stem Cell Patents, 25 BIOTECH. 
L. REP. 555 (Oct. 2006).  The two groups were the Foundation for Taxpayer and 
Consumer Rights (“FTCR”) and the Public Patent Foundation (“PUBPAT”).  Id. 
113
 Id. 
114
 KSR Int’l Co. v. Teleflex Inc., 127 S. Ct. 1727 (2007). 
115
 WARF Offers Free Licenses if Companies Agree to Work in State, 25 BIOTECH. L. 
REP. 683 (Dec. 2006). 
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patents issued in the United States,116 and were revoked by the PTO in 
March 2007 on the ground of “obviousness.”117 
 
[44]  Under the U.S. patent system inventions must be “new and useful” to 
be considered patentable.  This is according to 35 U.S.C. § 101, which 
provides that, “[w]hoever invents or discovers any new and useful process, 
machine, manufacture, or composition of matter, or any new and useful 
improvement thereof, may obtain a patent….”118  In addition, the 
invention needs to be “non-obvious” at the time it is made, to be 
considered new.  Section § 103 provides that  
 
[a] patent may not be obtained . . . if the differences 
between the subject matter sought to be patented and the 
prior art are such that the subject matter as a whole would 
have been obvious at the time the invention was made to a 
person having ordinary skill in the art to which said subject 
matter pertains.119 
 
[45]  In July 2006, two groups filed requests for reexamination and 
revocation of the “Thomson patents.”120  The groups alleged that the 
“Thomson patents” “were obvious over prior art, and were blocking 
scientific progress . . . .”121  They also argued that the patents were forcing 
researchers to leave the United States for other countries, where the 
“Thomson patents” are not recognized.122  In response to the requests for 
reexamination, the PTO explained that the standard of reexamination is 
whether there is “a substantial likelihood that a reasonable examiner 
would consider the teachings [of the cited publications] important in 
deciding the patentability of the claims.”123  The harm claimed by the two 
groups was irrelevant.124        
                                                 
116
 Rohrbaugh, supra note 109. 
117
 Lash, supra note 111. 
118
 35 U.S.C. § 101 (2000). 
119
 35 U.S.C. § 103 (2000). 
120
 Two Groups Try for Revocation of Human Embryonic Stem Cell Patents, 25 BIOTECH. 
L. REP. 555 (Oct. 2006).   
121Warf Offers Free Licenses if Companies Agree to Work in State, supra note 115. 
122
 Id. 
123
 Id. (alteration in original). 
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[46]  The PTO invalidated the three “Thomson patents” on the grounds of 
obviousness in March 2007 by a non-final decision.125  It appears that the 
PTO has followed in the footsteps of its European counterpart in rejecting 
unmodified human ES-cell patents.126  In Europe, the European Patent 
Convention has even adopted a strict rule excluding the patentability of 
any invention involving the use of human embryos for industrial or 
commercial purposes.127 
 
[47]  On the other hand, as John A. Robertson has observed, it may be 
naïve to expect that a government agency traditionally relying on scientific 
data, not politics, will be untainted by pro-life influence.128  Robertson 
cited the FDA’s refusal to approve non-prescription sales of Plan B, an 
emergency contraceptive, as an example.129  Robertson stated that 
“[d]espite near unanimous advisory committee approval of the benefits 
from over-the-counter sales of Plan B, the Commissioner of the FDA 
refused to approve it, disingenuously issuing a notice for further comment 
and rulemaking instead.”130 
 
[48]  Similarly, there is no guarantee that the PTO will be shielded from 
the influence of leading politicians’ moral and ethical views regarding 
human ES-cell issues.  Nevertheless, even if WARF appeals to a federal 
                                                 
125
 Lash, supra note 111. 
126
 See Rohrbaugh, supra note 109. 
127
 See European Patent Convention (“EPC”), part II, ch. VI, rule 23d, available at 
http://legis.obi.gr/espacedvd/legal_texts/epc/r23d.html#R23d (last visited Mar. 21, 2008). 
Exceptions to patentability: 
European patents shall not be granted in respect of biotechnological 
inventions which, in particular, concern the following: 
(a) processes for cloning human beings; 
(b) processes for modifying the germ line 
genetic identity of human beings; 
(c) uses of human embryos for industrial or 
commercial purposes; 
(d) processes for modifying the genetic identity 
of animals which are likely to cause them suffering 
without any substantial medical benefit to man or 
animal, and also animals resulting from such 
processes. 
128
 See Robertson, supra note 15, at 18-19. 
129
 Id. at 19.  
130
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Richmond Journal of Law & Technology Volume XIV, Issue 4 
 
20  
court challenging the PTO’s decision to revoke the “Thomson patents,” it 
is unlikely the patents will be reinstated in the wake of KSR International.  
 
C.  KSR INTERNATIONAL CO. V. TELEFLEX, INC. 
 
[49]  The Supreme Court issued a decision restricting the issuance of 
patents approximately one month after the PTO’s non-final decision 
revoking the first patents in this country issued to human ES-cell lines and 
methods of obtaining the cell lines.  In KSR International Co. v. Teleflex, 
Inc.,131 the Supreme Court rejected the Federal Circuit Court of Appeals 
“teaching, suggestion, or motivation” test (“TSM test”),132 and replaced it 
with an “expansive and flexible approach” to be used when determining 
the question of obviousness.133  Before KSR International, the Federal 
Circuit Court of Appeals had developed and adopted the more rigid TSM 
test.  These tests are necessary because a patent cannot be granted if the 
subject matter was obvious to a person having ordinary skill in the art, at 
the time the subject matter was invented.134 
 
[50]  The Federal Circuit’s TSM test was a way of “[s]eeking to resolve 
the question of obviousness with more uniformity and consistency . . . .”135  
Under the test, a court is obliged first to presume that the issued patent 
was valid and then to render its own independent judgment of obviousness 
based on a review of the prior art.136  A patent claim is only proved 
obvious if “‘some motivation or suggestion to combine the prior art 
teachings’ can be found in the prior art, the nature of the problem, or the 
knowledge of a person having ordinary skill in the art.”137  In other words, 
“unless the ‘prior art references address[ed] the precise problem that the 
patentee was trying to solve,’ the problem would not motivate an inventor 
to look at those references.”138  In addition, the fact that the PTO had 
                                                 
131
 KSR Int’l Co. v. Teleflex, Inc., 127 S. Ct. 1727 (2007). 
132
 Id. at 1730.   
133
 Id. at 1739. 
134
 35 U.S.C. § 103 (2000). 
135
 KSR Int’l Co., 127 S. Ct. at 1734. 
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 Id. at 1739. 
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 Id. at 1734. 
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rejected a broader version of the claim has no place in the analysis under 
the TSM test.139 
 
[51]  In rejecting the TSM test, the Supreme Court replaced it with an 
expansive and flexible approach by stating that, “[t]he combination of 
familiar elements according to known methods is likely to be obvious 
when it does no more than yield predictable results.”140  The Court further 
noted that “[o]ne of the ways in which a patent’s subject matter can be 
proved obvious is by noting that there existed at the time of invention a 
known problem for which there was an obvious solution encompassed by 
the patent’s claims.”141  Moreover, courts are invited to look at any 
secondary considerations that would prove instructive, wherever 
appropriate.142  Under the test, a court can take account of any inferences 
and creative steps that a person of ordinary skill in the art would 
employ.143 
 
[52]  The Supreme Court’s flexible approach has raised concerns that the 
issuance of patents, especially in the field of biotechnology, will become 
unpredictable and deter private investment as a result.  As the 
Biotechnology Industry Organization has argued in its amicus brief, if the 
standards of obviousness under 35 U.S.C. § 103(a) become less objective, 
the increased uncertainty about the availability of patent rights will have a 
direct impact on investment incentives in biotechnology, and will deter 
investment within the industry.144  In addition, “[i]nventors would have no 
predictable defenses against [challengers] seeking to invalidate 
biotechnology inventions many years, or even decades, after the ideas 
were first conceived.”145 
 
[53]  Human ES-cell research, as a subset of the biotechnology industry, 
would be particularly adversely affected by the flexible obviousness 
approach.  Many patentable inventions in biotechnology, including human 
                                                 
139
 Id. at 1739. 
140
 Id. 
141
 Id. at 1742. 
142
 Id. at 1739. 
143
 Id. at 1741. 
144
 Brief for Biotechnology Industry Organization as Amicus Curiae Supporting 
Respondents, KSR Int’l Co. v. Teleflex, Inc., 127 S. Ct. 1727 (2007) (No. 04-1350), at 2. 
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ES-cell research, spring from known components and methodologies 
found in prior art.  Such combinations of prior art may be logical to try, 
because the advances “are only won through trial and error, at great effort 
and expense, and with only a low probability of success in achieving the 
claimed invention . . . .”146  Furthermore, “[r]esearch and development in 
the biotechnology industry is particularly expensive, time-consuming, and 
presents an unusually high-risk investment that relies on an objective and 
predictable application of obviousness law.”147 
 
[54]  In the wake of KSR International, not only are the “Thomson 
patents” unlikely to be reinstated in a federal court, but more human ES-
cell patents which have been issued by the PTO may be vulnerable to the 
challenge of invalidation.  The withdrawal of private funding from such 
research is at stake. 
 
[55]  In addition to the restriction on the issuance of patents and federal 
funding, the aborted congressional legislation supporting human ES-cell 
research, and the struggle of California’s funding for such research, the 
Supreme Court has extensively expanded its abortion jurisprudence.  The 
recently extended abortion jurisprudence established in Gonzales v. 
Carhart148 may have paved the way for the Court to invalidate legislation 
approving public funding for human ES-cell research, which is deemed by 
                                                 
146
 Id. at 6.  Following the Supreme Court’s KSR International decision, the Patent and 
Trademark Office published Examination Guidelines to help USPTO examiners make 
decisions regarding the obviousness of claimed inventions.  In the Guidelines, the PTO 
laid out five rationales to support rejections under 35 U.S.C. § 103 (2008).  One of the 
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Biotechnology Industry Organization’s concern that the KSR International decision has a 
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the Supreme Court Decision in KSR International Co. v. Teleflex, Inc., 72 Fed. Reg. 
57,526 (Oct. 10, 2007). 
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 Brief for Biotechnology Industry Organization as Amicus Curiae Supporting 
Respondents, KSR Int’l Co. v. Teleflex, Inc., 127 S. Ct.1727 (2007) (No. 04-1350), at 8. 
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some as a means of destroying prospective human lives in conflict with 
the states’ interest in promoting and preserving life. 
 
V.  THE TEACHINGS OF THE SUPREME COURT’S ABORTION JURISPRUDENCE 
 
[56]  Human ES-cell research and abortion are both arguably affecting the 
“prospective humans’ right to live,” from the opponents’ point of view.  
Nevertheless, within the anti-abortion movement itself, the opponents of 
abortion do not share the same view concerning human ES-cell 
research.149  Some consider themselves purists, who oppose both abortion 
and stem cell research, and the others see stem cell research as a matter of 
pragmatism.150  Though the Supreme Court has yet to decide the issue 
concerning human ES-cell research or an embryo’s right to live under the 
U.S. Constitution, the Court’s recent opinion regarding the propriety of 
abortion procedures may have shed some light on the Court’s view 
concerning the propriety of human ES-cell research. 
 
A.  THE APPLICABILITY OF THE ABORTION JURISPRUDENCE 
 
[57]  Before examining the Supreme Court’s abortion jurisprudence, it is 
important to note the similarities and differences between embryos and 
fetuses.  Embryos and fetuses are similar in that they both have the 
potential of becoming human beings if an adequate supporting system has 
been given, though the complexity and the extent of support varies.151 
                                                 
149
 Talev, supra note 73; see also Grinnell, supra note 42.  As Frederick Grinnell has 
stated: 
The discovery that human eggs could be fertilized 
outside the body coincided more or less with the 
1973 Supreme Court decision in Roe v. Wade that 
made abortion legal.  Abortion and in vitro 
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with those who oppose abortion arguing that research 
that leads to the destruction of embryos is equivalent 
to abortion.  
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 Talev, supra note 73; see also Robertson, supra note 15, at 26 (stating “[i]f there is a 
right to create and discard embryos to achieve pregnancy, then a fortiori the right to 
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[58]  The differences between embryos and fetuses include not only that 
the fetuses are at a developmental stage much closer to a human form,152 
but also that the fetuses are a life form with much complex biological 
entanglement with its bearing mother, while embryos in the fertilization 
clinics are a life form already separated from the persons originally 
bearing the germ cells by a medical procedure.  Arguably, an embryo 
frozen in the fertilization clinic is akin to the fetal tissue which has been 
taken out of the mothers’ womb by an abortion procedure, rather than 
viable fetuses.  Whether an embryo has a chance to become a human being 
depends on another intrusive medical procedure to place the embryo in a 
woman’s womb, and the possibility of carrying the embryo to term is 
relatively low.153  
 
[59]  The chance of an embryo becoming a human being is much lower 
than a fetus in the first trimester, even if there is a woman willing to accept 
the intrusive medical procedure to place the embryo in her womb.154  The 
first obstacle is the low implantation rate.  It has been shown that only one 
in every four embryos can be successfully implanted in a woman’s womb 
after the medical procedure.155  If the recipient is older, a technique called 
“multiple embryo transfers,” which allows multiple embryos to compete 
for implantation, is usually needed to secure a better result.156  In other 
words, a large proportion of embryos will be screened out by the 
recipient’s body even though they are deemed normal and healthy. 
 
[60]  In addition, the chance of carrying a human embryo to term is even 
lower if the embryo has been frozen and thawed.  The miscarriage rates 
are higher among pregnancies conceived with frozen and thawed embryos, 
                                                 
152
 Id. at 26. 
153
 See American Pregnancy Association, In Vitro Fertilization: IVF, 
http://www.americanpregnancy.org/ 
Infertility/ivf.html (last visited Mar. 23, 2008). 
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 See id.  
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 Steven D. Spandorfer, The Impact of Maternal Age and Ovarian Age on Fertility, 
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which are the subjects of human ES-cell research, compared to those using 
freshly fertilized embryos.157 
 
[61]  As a result, though the fetuses and embryos are both arguably 
prospective humans, the chance of an embryo becoming a human being is 
much lower than a fetus.  Judging from the already-high natural 
miscarriage risk of a fetus in the first trimester,158 it may be a step too far 
to recognize embryos as prospective humans. 
 
[62]  On the other hand, it is not clear whether the assertion that embryos 
are prospective humans will be accepted by the Court.  Nevertheless, in 
the wake of Gonzales v. Carhart,159 Mary Doe’s destiny in a courtroom is 
probably more like a fetus, rather than a frozen embryo (as it should be), 
which statistically has a much lower chance to develop into a human 
being. 
 
B.  GONZALES V. CARHART 
 
[63]  Similar to human ES-cell research, the issue regarding whether to 
ban partial-birth abortions—which allegedly involves piercing the fetal 
skull with scissors or crushing it with forceps160—was a tug of war 
between Congress and President Clinton.  In 1996 and 1997, President 
Clinton twice vetoed congressional legislation on this issue.161  In 2003, 
Congress passed the Partial-Birth Abortion Ban Act,162 and President Bush 
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 See generally Jeanie Lerche Davis, Infertility Treatments and Miscarriage? Assisted 
Reproductive Treatments not Shown to Increase Miscarriages, 
http://www.webmd.com/infertility-and-reproduction/news/20030502/infertility-
treatments-miscarriage (last visited July 31, 2007); Grinnell, supra note 42 (stating “[i]n 
2000 . . . statistics from the Centers for Disease Control and prevention showed that the 
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signed the Act into law.163  The validity of the Partial-Birth Abortion Ban 
Act later became the issue in Gonzales v. Carhart.164 
 
[64]  Gonzales is the latest teaching of the Supreme Court’s “abortion 
jurisprudence.”  Doctors performing second-trimester abortions 
challenged the constitutionality of the Partial-Birth Abortion Ban Act and 
sought a permanent injunction against its enforcement.165  The Court held 
that, among other things, the ban on the abortion procedure did not impose 
an undue burden on a woman’s right to abortion either based on the Act’s 
over-breadth or lack of a health exception.166 
 
[65]  For the purpose of this article, it is important to note that the 
Supreme Court in Gonzales expressly abandoned the distinction of fetal 
“viability” in weighing the propriety of an abortion procedure.  In 
Gonzales, the Court found that the Partial-Birth Abortion Ban Act applied 
both previability and postviability.167  By rejecting the distinction of fetal 
viability, the Court further stated that “a fetus is a living organism while 
within the womb, whether or not it is viable outside the womb.”168 
 
[66]  The dissent commented that the majority’s decision in Gonzales was 
alarming.169  As Justice Ginsburg stated in the dissenting opinion, the 
Gonzales decision has blurred the line between previability and 
postviability abortions as firmly drawn in Planned Parenthood v. 
Casey.170 
 
[67]  Consequently, a state’s interest in preserving and promoting life may 
extend to “embryos” without the need for weighing other competing 
interests since the outset of the pregnancy.  Although the Court 
acknowledged in Gonzales that “the State has legitimate interests from the 
outset of the pregnancy in protecting the health of the woman and the life 
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of the fetus that may become a child,”171 and that it was the principle that 
“require[d] the most extended discussion,”172 the Court nevertheless 
upheld the state’s interest in preserving fetal life by stating that, 
“[w]hatever one’s views concerning the Casey joint opinion, it is evident a 
premise central to its conclusion--that the government has a legitimate and 
substantial interest in preserving and promoting fetal life . . . .”173  As 
Justice Ginsberg stated in the dissent, “for the first time since Roe, the 
Court blesses a prohibition with no exception safeguarding a woman’s 
health.”174 
 
[68]  Furthermore, the Gonzales Court reaffirmed the government’s 
interest in “protecting the integrity and ethics of the medical 
profession.”175  The Court deferred to the congressional finding that the 
partial-birth abortion is a “brutal and inhumane procedure . . .”176 and 
recognized that Congress “was concerned with ‘draw[ing] a bright line 
that clearly distinguishes abortion and infanticide.’”177  The Gonzales 
Court reaffirmed the government’s regulatory power to bar certain 
medical procedures by stating that 
 
[w]here it has a rational basis to act, and it does not impose 
an undue burden, the State may use its regulatory power to 
bar certain procedures and substitute others, all in 
furtherance of its legitimate interests in regulating the 
medical profession in order to promote respect for life, 
including life of the unborn.178 
 
[69]  However, the Gonzales Court’s conclusion that the Partial-Birth 
Abortion Ban Act does not impose an undue burden was rooted in the 
considerations that alternatives to the prohibited procedure were 
available.179  The medical profession is obligated to adopt “less shocking 
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methods” to accommodate legislative demand, if they are available.180  In 
addition, the Gonzales Court acknowledged that where there is medical 
and scientific uncertainty, the courts should give state and federal 
legislatures wide discretion to pass legislation in such areas.181 
 
[70]  To a certain extent, Gonzales may be viewed as a double-edged 
sword if the issue regarding the validity of legislation sought to fund 
human ES-cell research is brought to court.  On one hand, the opponents 
of human ES-cell research can argue that in the wake of Gonzales, the 
government has legitimate interests in preserving and promoting life 
regardless of the viability of the living organism outside the womb, 
including an embryo frozen in liquid nitrogen.  In furtherance of that 
interest, the government is not obligated to weigh other competing 
interests—such as the imminent medical needs of patients suffering from 
incurable diseases—since the abortion statute in Gonzales was upheld by 
the Court even though it did not provide an exception to protect a 
woman’s health. 
 
[71]  On the other hand, the proponents of human ES-cell research may 
argue that contrary to the congressional finding in Gonzales, human ES-
cell research is not a “brutal and inhumane” procedure.  Even if human 
ES-cell research is considered inherently or impliedly “brutal and 
inhumane,” there is no alternative available because as discussed earlier, 
neither the reprogramming phenomenon nor the use of “dead” embryos is 
a reliable technique at this stage.  Moreover, as the Gonzales Court has 
stated, where there is medical and scientific uncertainty, the courts should 
give legislatures wide discretion to pass legislation in such areas.182 
 
[72]  Nevertheless, to some commentators’ dismay, it may not be realistic 
to expect the Supreme Court to play a significant role in upholding rights 
to research or rights to treatment after Gonzales, if lawsuits regarding the 
restrictions on human ES-cell research arise.  As John A. Robertson has 
suggested, there are situations when the judiciary should become more 
involved in the stem cell issues:183  When restrictions on research become 
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intolerable and lawsuits about rights to research arise,184 and when safe 
and effective treatments are available but cannot be used, and 
constitutional rights to treatment are asserted.185  In light of Gonzales, the 
best a proponent of stem cell research may be able to expect from the 
Supreme Court would be that the Court would defer to the legislature 
rather than imposing its own view on the legislature following Gonzales.  
This is in light of the fact that the Gonzales decision has expanded the 
justification of the state’s interest in preserving and promoting unborn life 
before viability, even if at the expense of the health of a woman, who is a 
born person. 
 
[73]  In addition, deriving stem cells from an embryo may be viewed as 
“infanticide” if the distinction of viability no longer exists.  The Gonzales 
Court sought to distinguish abortion from infanticide.186  It was the latter 
that justified the ban on the partial-birth abortion procedure.187  The 
physicians’ overt act causing the fetus’ death, rather than delivery, incurs 
liability.188  It does not bode well if the Court imposes a similar view on 
the issue of human ES-cell research. 
 
[74]  After Gonzales, it is not likely that a legislative effort authorizing 
public funding for human ES-cell research, which is in conflict with the 
state’s interest in promoting and preserving life, can survive in the 
Supreme Court.  Contrary to John A. Robertson’s view before the 
Gonzales decision that “a greater role for the judiciary [is favored if] direct 
bans on privately funded [human] ESC therapies or on the research 
necessary to produce them,”189 the best a proponent of human ES-cell 
research can expect from the Court after Gonzales may be deference by 
the Court to the legislature. 
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VI.  CONCLUSION 
 
[75]  The United States has effectively banned human ES-cell research in 
the absence of a direct prohibition declared by the government.  The joint 
efforts of the Executive Branch and the Supreme Court have essentially 
made the revival of human ES-cell research in this country unlikely.  Even 
if there is a legislative effort attempting to support such research, again, 
the legislation is less likely to survive the Supreme Court’s muster after 
Gonzales. 
 
[76]  Nevertheless, the legislative branch is better situated in conducting 
the balancing test to weigh the public interest that will flow from human 
ES-cell research against the ethical and moral concerns arising from the 
use of human ES-cells in research or treatment.190  Nonetheless, the 
Supreme Court’s Gonzales decision may have paved the way for a 
challenger’s success in claiming the frozen embryo’s right to live.  The 
issue in the abortion case revolved around medical procedures which were 
inherently cruel and inhumane in terminating fetuses’ lives when 
alternative medical procedures were available.  However, there exists no 
such cruel and inhumane procedure191 in human ES-cell research, and 
reliable alternative techniques are not available. 
 
[77]  Traditionally, human ES-cell research has relied on private money, 
and the patent system has played an important role in attracting private 
investment.  However, in the wake of the Supreme Court’s KSR 
International decision, the issuance of patents in the field of 
biotechnology has become unpredictable.  It does not seem likely that 
private investments will continue to play a significant role in ES-cell 
research, since the issuance of patents has been restricted and the strictures 
further increase the risk of investment in an industry where the risk is 
already high. 
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[78]  In sum, the government has numerous methods that it can use to 
suffocate a disfavored subject matter.  Though the Executive Branch and 
the Supreme Court may not have intended to ban the research, they have 
adopted an approach essentially suffocating such research. 
